title: The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges.
abstract: Multiple Sclerosis (MS) is an inflammatory demyelinating disorder which affects the central nervous system. Multiple sclerosis treatment has traditionally focused on preventing inflammatory damage to the myelin sheath. Indeed, all currently available disease modifying agents are immunomodulators. However, the limitations of this approach are becoming increasingly clear, leading to the exploration of other potential therapeutic strategies. In particular, targeting the endogenous remyelination system to promote replacement of the lost myelin sheath has shown much promise. As our understanding of remyelination biology advances, the realization of a remyelinating therapeutic comes closer to fruition. In our review, we aim to summarize the limitations of the current immune focused treatment strategy and discuss the potential of remyelination as a new treatment method. Finally, we aim to highlight the challenges in the identification and development of such therapeutics.
authors.affiliation: Neurotherapeutics Research Group, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Murphy
authors.forename: Keith J
authors.initials: KJ
authors.lastname: Murphy
authors.forename: Mark
authors.initials: M
authors.lastname: Pickering
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000639:trends*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism*; D009186:Myelin Sheath / Q000378:metabolism*
keywords: multiple sclerosis; myelin; neurodegeneration; oligodendrocyte; remyelination